EUVIMEDEUVIMED entdecken
Crossref

Deubiquitinating Enzymes in Colorectal Cancer: Molecular Mechanisms and Therapeutic Opportunities

Jia Wang, Wan Hu Jin, Chang-Zhu Pei, Gang Li

Oncology Research · 2026 · 1-10

DOI: 10.32604/or.2026.088965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Jia Wang und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: Colorectal cancer (CRC) remains a major cause of cancer-related mortality, and therapeutic resistance continues to limit treatment efficacy. Deubiquitinating enzymes (DUBs), which regulate protein stability and function by removing ubiquitin, play critical roles in CRC progression, metastasis, and treatment resistance. This review summarizes the roles of major DUB families in oncogenic signaling, tumor microenvironment (TME) remodeling, metabolic reprogramming, and therapeutic response. DUBs modulate key pathways, including Wnt/ β -catenin, MAPK, and PI3K/Akt, and promote immune evasion by regulating antigen presentation, immune checkpoints, and immuno-suppressive cell recruitment. They also support metabolic adaptation and tumor survival through the regulation of glycolysis, hypoxia-associated signaling, ferroptosis, and apoptosis. In addition, DUB-mediated enhancement of DNA damage repair and maintenance of cancer stemness contribute to resistance to anticancer therapies. Although DUBs represent promising therapeutic targets and potential biomarkers, functional redundancy and context-dependent activities remain major challenges for clinical translation. Emerging strategies, including rational combination therapies, proteolysis-targeting chimeras, and deubiquitinase-targeting chimeras, may improve therapeutic precision. Integrating DUB-associated biomarkers with consensus molecular subtypes and TME characteristics could further facilitate patient stratification and personalized treatment. Elucidating the context-specific functions of DUBs will be essential for translating these insights into effective therapeutic strategies for CRC.

Zitieren

APA

Wang, J., Jin, W. H., Pei, C., & Li, G. (2026). Deubiquitinating Enzymes in Colorectal Cancer: Molecular Mechanisms and Therapeutic Opportunities. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.088965

Vancouver

Wang J, Jin WH, Pei C, Li G. Deubiquitinating Enzymes in Colorectal Cancer: Molecular Mechanisms and Therapeutic Opportunities. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.088965

BibTeX
@article{Wang2026,
  author = {Wang, Jia and Jin, Wan Hu and Pei, Chang-Zhu and Li, Gang},
  title = {Deubiquitinating Enzymes in Colorectal Cancer: Molecular Mechanisms and Therapeutic Opportunities},
  journal = {Oncology Research},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {1--10},
  doi = {10.32604/or.2026.088965}
}
Kostenlos starten →